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Abstract
The extracellular matrix (ECM) plays a significant role in the
mechanical behaviour of the lung parenchyma. The ECM is
composed of a three-dimensional fibre mesh that is filled with
various macromolecules, among which are the glycosaminoglycans
(GAGs). GAGs are long, linear and highly charged heterogeneous
polysaccharides that are composed of a variable number of
repeating disaccharide units. There are two main types of GAGs:
nonsulphated GAG (hyaluronic acid) and sulphated GAGs
(heparan sulphate and heparin, chondroitin sulphate, dermatan
sulphate, and keratan sulphate). With the exception of hyaluronic
acid, GAGs are usually covalently attached to a protein core,
forming an overall structure that is referred to as proteoglycan. In
the lungs, GAGs are distributed in the interstitium, in the sub-
epithelial tissue and bronchial walls, and in airway secretions.
GAGs have important functions in lung ECM: they regulate
hydration and water homeostasis; they maintain structure and
function; they modulate the inflammatory response; and they
influence tissue repair and remodelling. Given the great diversity of
GAG structures and the evidence that GAGs may have a
protective effect against injury in various respiratory diseases, an
understanding of changes in GAG expression that occur in
disease may lead to opportunities to develop innovative and
selective therapies in the future.
Introduction
The alveolar wall is composed of an epithelial cell layer and
its basement membrane, the capillary basement membrane
and endothelial cells, and a thin layer of interstitial space lying
between the capillary endothelium and the alveolar epithelium,
which is the extracellular matrix (ECM) [1]. In some areas, the
two basement membranes are physically fused to reduce the
diffusion distance as much as possible. In the segments
where the two basement membranes are not fused, the
interstitium is composed of cells, a macromolecular fibrous
component and the fluid phase of the ECM; here the ECM
functions as a three-dimensional mechanical scaffold charac-
terized by a fibrous mesh consisting mainly of collagen types I
and III (providing tensile strength) and elastin (conveying
elastic recoil) [2,3]. The three-dimensional fibre mesh is filled
with other macromolecules, mainly glycosaminoglycans
(GAGs), which are the major components of the nonfibrillar
compartment of the interstitium [4].
The structure of the lung ECM plays several important roles,
including mechanical (it provides tensile and compressive
strength and elasticity, with a strong and expandable frame-
work that supports the fragile alveolar-capillary intersection),
gas exchange (it offers a low resistive pathway, allowing
effective gas exchange), protective (it acts as a buffer against
retention of water) and organizational (it controls cell
behaviour by binding of growth factors and interaction with
cell surface receptors) [2,4].
Although many studies have described the roles played by
proteoglycans in a wide range of pulmonary diseases [5-8],
the actions of GAGs in the lung parenchyma are much less
well understood. Study of the ECM and GAGs is important
because it may improve our pathophysiological knowledge on
the development of oedema and specific interstitial lung
diseases, it may permit early diagnosis of ECM alterations
and lung remodelling processes, and it may promote
development of ventilatory and pharmacological therapeutic
strategies.
Review
Bench-to-bedside review: The role of glycosaminoglycans in
respiratory disease
Alba B Souza-Fernandes1, Paolo Pelosi2 and Patricia RM Rocco3
1Laboratory of Pulmonary Investigation, Carolos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Ilha do Fundão, 21949-900,
Rio de Janeiro, Brazil
2Department of Ambient, Health and Safety, University of Insubria, Viale Borri 57, 21100 Varese, Italy
3Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Ilha do Fundão, 21949-900, 
Rio de Janeiro, Brazil
Correspondence: Patricia RM Rocco, prmrocco@biof.ufrj.br
Published: 10 November 2006 Critical Care 2006, 10:237 (doi:10.1186/cc5069)
This article is online at http://ccforum.com/content/10/6/237
© 2006 BioMed Central Ltd
APC = activated protein C; ARDS = acute respiratory distress syndrome; ATIII = antithrombin III; DIC = disseminated intravascular coagulation;
ECM = extracellular matrix; FGF = fibroblast growth factor; GAG = glycosaminoglycan; GAS = group A streptococci; IL = interleukin; LPS =
lipopolysaccharide; PG = proteoglycan; Pip = pulmonary interstitium pressure; PLA2 = phospholipase A2; TFPI = type 1 tissue factor pathway
inhibitor; TLR = Toll-like receptor; TNF = tumour necrosis factor.
Page 2 of 16
(page number not for citation purposes)
Critical Care    Vol 10 No 6 Souza-Fernandes et al.
The present review discusses the biochemical characteristics
of GAGs, their biological roles and mechanisms of action in
several respiratory diseases, and their potential therapeutic
effects.
Glycosaminoglycans
GAGs are long, linear and heterogeneous polysaccharides,
which consist of repeating disaccharide units with sequences
that vary in the basic composition of the saccharide, linkage,
acetylation, and N-sulphation and O-sulphation; these
disaccharide units are galactose, galactosamine, N-acetyl-
galactosamine-4-sulphate and galacturonic acid. The chain
length of GAGs can range from 1 to 25,000 disaccharide
units, and their molecular weights vary over three orders of
magnitude, implying that the polymer chains can contain as
many as 104 units with great variability in size and structure
[9].
There are two main types of GAGs: nonsulphated GAG
(hyaluronic acid) and sulphated GAGs (heparan sulphate and
heparin, chondroitin sulphate, dermatan sulphate and keratan
sulphate). With the exception of hyaluronic acid, GAGs are
usually covalently attached to a protein core, forming an
overall structure referred to as proteoglycans [10] (Figure 1).
Hyaluronic acid
Hyaluronic acid is the most abundant nonsulphated GAG in
the lung ECM. Hyaluronic acid differs from the other GAGs
because it is spun out from the cell membrane, rather than
being secreted through the Golgi, and because it is
enormous (107 Da, which is much larger than other GAGs).
Hyaluronic acid is a naturally occurring, linear polysaccharide
that is composed of up to 10,000 disaccharides constituted
by an uronic acid residue covalently linked to an N-acetyl-
glucosamine, with a flexible and coiled configuration. It is a
ubiquitous molecule of the connective tissue that is primarily
synthesized by mesenchymal cells. It is a necessary molecule
for the assembly of a connective tissue matrix and is an
important stabilizing constituent of the loose connective
tissue [11]. A unique characteristic of hyaluronic acid, which
relates to its variable functions, is its high anion charge, which
attracts a large solvation volume; this makes hyaluronic acid
an important determinant of tissue hydration [5]. Excessive
accumulation of hyaluronic acid in the interstitial tissue may
therefore immobilize water and behaves as a regulator of the
amount of water in the interstitium [11]. Hyaluronic acid is
present in the ECM, on the cell surface and inside the cell,
and its functions are related to its localization [12]. Hyaluronic
acid is also involved in several other functions, such as tissue
repair [13,14] and protection against infections and proteo-
lytic granulocyte enzymes [15].
Sulphated glycosaminoglycans
GAGs of this type are synthesized intracellularly, sulphated,
secreted and usually covalently bound into proteoglycans.
They are sulphated polysaccharides composed of repeating
disaccharides, which consist of uronic acid (or galactose) and
hexosamines. The proteoglycan core proteins may also link
carbohydrate units including O-linked and N-linked
oligosaccharides, as found in other glycosylated proteins. The
polyanionic nature of GAGs is the main determinant of the
physical properties of proteoglycan molecules, allowing them
to resist compressive forces and simultaneously to maintain
tissue hydration. They are much smaller than hyaluronic acid,
usually being only 20 to 200 sugar residues long [16,17].
Within the lung parenchyma the most abundant sulphated
GAG is heparan sulphate, a polysaccharide that is expressed
on virtually every cell in the body and comprises 50% to 90%
of the total endothelial proteoglycans [18]. Heparan sulphate
has the most variable structure, largely because of variations in
the sulphation patterns of its chains. In addition to sequence
diversity, its size ranges from 5 to 70 kDa. Although it is initially
produced in a cell surface bound form, it can also be shed as
a soluble GAG. The mechanism of action of heparan sulphate
includes specific, noncovalent interactions with various
proteins; this process affects the topographical destination,
half-life and bioactivity of the protein. Furthermore, heparan
sulphate acts on morphogenesis, development and
organogenesis [19]. It is also involved in a variety of biological
processes, including cell-matrix interactions and activation of
chemokines, enzymes and growth factors [19,20].
Heparin is the most highly modified form of heparan sulphate.
This GAG, which can be considered an over-sulphated
intracellular variant of heparan sulphate, is commonly used as
an anticoagulant drug [19]. Heparin and heparan sulphate
are closely related and may share many structural and
functional activities. The lung is a rich native source of
Figure 1
Schematic structure of glycosaminoglycan and proteoglycan. Note that
the hyaluronic acid is not linked to a protein core. Heparan sulphate,
dermatan sulphate and chondroitin sulphate are connected to
proteoglycan via a serine residue.
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heparin. This abundance of heparin may be accounted for by
the fact that the lung is rich in mast cells, which may be
heparin’s sole cell of origin [21]. Mast cell heparin resides in
secretory granules, where most of the GAG chains are linked
to a core protein (serglycin), forming macromolecular proteo-
glycans that are much larger than commercial heparin. Very
little heparin is incorporated into cell surface proteoglycans of
epithelial and endothelial cells; these are more likely to
contain heparan sulphate, which is under-sulphated compared
with heparin. Some heparan sulphate chains of vascular
endothelium contain short heparin-like sequences [20].
However, most native lung heparin is locked up in mast cells
as large proteoglycans. This does not necessarily mean that
heparin’s physiological action resides exclusively within cells,
because stimulated mast cells secrete heparin outside of the
cell along with granule-associated mediators, such as
histamine, chymase and tryptase [22].
Proteoglycans
In the lung, three main proteoglycan (PG) families may be
distinguished based on GAG composition, molecular weight
and function: chondroitin suphate containing PG (versican),
heparan sulphate containing PGs (perlecan and glypican),
chondroitin and heparan sulphate containing PGs (syndecan)
and dermatan sulphate containing PGs (decorin). They are
localized in different areas of the ECM: versican resides in the
pulmonary interstitium, perlecan in the vascular basement
membrane, decorin in the interstitium and in the epithelial
basement membrane linked with collagen fibrils, and
syndecan and glypican in the cell surface (Figure 2).
Versican is a large molecule (>1000 kDa) that is found
around lung fibroblasts and blood vessels in regions not
occupied by the major fibrous proteins collagen and elastin. It
is localized mainly in the interstitium, creating aggregates with
hyaluronic acid [17]. The precise function of versican is
unclear but it is thought to be involved in tissue hydration. It
may form aggregates with hyaluronic acid, fibronectin and
various collagens, playing an important role in cell-matrix
interaction. It has been shown that versican is linked with
smooth muscle cells in the walls of airways and pulmonary
vessels, inhibits cell-matrix adhesion [23], regulates
differentiation of mesenchymal cells and plays a specific role
in matrix synthesis, favouring wound healing.
Perlecan is the largest PG in the lung, with its core
possessing about 4400 amino acids. Perlecan is a typical
component of vascular basement membrane [24], although it
has been also identified within the ECM of some tissues,
close to the basement membrane. Indeed, its complex core
protein has the potential to interact with numerous proteins.
In the basement membranes it provides a filtration barrier
interacting with collagen IV, limiting the flow of macro-
molecules or cells between two tissue compartments. It also
regulates the interaction of the basic fibroblast growth factor
(FGF) with its receptor and modulates tissue metabolism.
Syndecan and glypican are densely arranged in the cell
surface [25]. The function of syndecan is commonly
associated with its heparan sulphate chains and its inter-
action with heparin binding growth factors or extracellular
Available online http://ccforum.com/content/10/6/237
Figure 2
Extracellular matrix components in lung parenchyma. CS, chondroitin sulphate; DS, dermatan sulphate; HS, heparan sulphate.
proteins such as fibronectin and laminin, and it plays a role in
wound healing [26].
Decorin is the smallest dermatan sulphate containing PG.
The presence of decorin alters the kinetics of fibril formation
and the diameter of the resulting fibril [17,25], modulating
tissue remodelling. Indeed, its name was derived from its
surface decoration of collagen fibrils when viewed under an
electron microscope.
These findings indicate that the function of PGs and GAGs in
the lung is not limited to maintenance of mechanical and fluid
dynamic properties of the organ. These molecules also play
roles in tissue development and recovery after injury, inter-
acting with inflammatory cells, proteases and growth factors.
Thus, the ECM transmits essential information to pulmonary
cells that regulates their proliferation, differentiation and
organization. The structural integrity of the pulmonary
interstitium depends largely on the balance between the
regulation of synthesis and degradation of ECM components.
Glycosaminoglycans and interstitial pressure
The efficiency of the alveolar-capillary membrane mostly
depends on the hydration of the interstitial layer in the
alveolar septa. In the tissue, fluid is partitioned into two
components that are in equilibrium with each other: water
molecules that are chemically bound to the polyanionic
hyaluronic acid and proteoglycans; and water that freely
moves across the porous mesh of extracellular fibrous macro-
molecules.
The very thin alveolar-capillary membrane reflects a condition
of minimum hydration volume of the interstitial compartment.
Lung water content depends on several factors, such as
transcapillary balance of pressures (Starling balance), tissue
forces transmitted through the interstitial matrix related to the
degree of lung expansion, forces arising from surface tension
phenomena at the alveolar-air interface, and lymph fluid
drainage [27]. GAGs are responsible for two important
aspects of microvascular and interstitial fluid dynamics,
namely the sieving properties of the capillary membrane and
of the matrix, and the compliance of the interstitial tissue. For
example, the relatively high number of chondroitin sulphate
chains imparts a high anion charge to the macromolecule,
allowing it to exhibit marked hydrophilic properties and to
control the hydration of the interstitial tissues. Heparan
sulphate chains account for specific interaction properties in
basement membrane organization, receptor functions, and
cell-cell and cell-matrix interactions [27].
The hydraulic pressure of the liquid phase of the pulmonary
interstitium (pulmonary interstitium pressure [Pip]) depends
on the total tissue hydration as well as other mechanical
factors such as the tissue stress related to lung volume and
the alveolar surface tension phenomenon [28]. In addition,
regional differences in Pip can be caused by the following:
the interdependence phenomenon (the stress that acts on
the outer surface of rigid structures such as bronchi and
vessels is greater than that on the pleural surface), the gravity
distribution of regional lung expansion and the interaction
between lung and chest wall. Thus, Pip reflects the dynamic
situation resulting from the complex interaction between
these factors. Any change in one set of forces will influence
the others. The result of this complex interaction is that a
change in one set of forces might cause a perturbation in the
extravascular water balance, leading to lung oedema [27].
Glycosaminoglycans and interstitial plasma protein
distribution
The ionic solute concentration of free interstitial fluid
essentially mirrors the plasma content; indeed, because these
solutes have a molecular radius that is smaller than that of the
endothelial intercellular clefts, they freely equilibrate between
plasma and extravascular fluid. In fact, the three dimensional
‘porous-like’, water-filled mesh established by GAGs
constitutes a selective sieve of variable porous size and
charge density [29]. The functional result of this pheno-
menon, termed ‘volume exclusion’, is a restriction of the
interstitial fluid volume available for proteins that, because of
their large size, cannot diffuse through the fibrous, porous
mesh [30]. In the normal lung, the mean albumin excluded
fraction (the percentage of interstitial fluid volume not
available to protein distribution) is about 70% [31].
Consequently, proteins are allowed to equilibrate in only 30%
of the available interstitial fluid volume. Thus, the normal lung
behaves differently from other tissues such as skeletal muscle
or skin, whose normal albumin distribution volume is as low
as about 30% [31]. Hence, compared with other tissues, the
normal lung parenchyma exhibits a tight fibrous structure that
is highly restrictive with respect to plasma proteins.
Glycosaminoglycans and lung oedema
The early phase of interstitial oedema implies an increase in
interstitial fluid pressure with no significant change in
interstitial fluid volume because of the low tissue compliance.
A low compliance conferred by the structure of the matrix
represents an important ‘tissue safety factor’ to counteract
further progression of pulmonary oedema. As the severity of
oedema progresses, Pip drops back to zero and
subsequently remains unchanged, despite a marked increase
in the wet weight:dry weight ratio of the lung. As oedema
develops into a more severe condition, fluid filtration occurs
down a transendothelial Starling pressure gradient that is
less than that in the basal state, because of the progressive
increase in interstitial fluid pressure. Hence, at least two
factors interact to determine the development of pulmonary
oedema, namely loss of the tissue safety factor and
augmented microvascular permeability [27].
In hydraulic oedema, biochemical analysis of tissue structure
reveals an initial fragmentation of chondroitin sulphate proteo-
glycan caused by mechanical stress and/or proteolysis. In
Critical Care    Vol 10 No 6 Souza-Fernandes et al.
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lesional oedema, the partial fragmentation of heparan
sulphate proteoglycan is mainly due to enzymatic activity. The
progression toward severe oedema is similar for both types of
oedema because the activation of tissue metalloproteinases
leads to extended fragmentation of chondroitin sulphate
proteoglycan, causing a marked increase in tissue compliance
and therefore a loss in tissue safety factor, and of heparan
sulphate proteoglycan, leading to an increase in micro-
vascular permeability [27,32,33].
Recent data also suggest that the integrity of the heparan
sulphate proteoglycan is required to maintain the three-
dimensional architecture of the matrix itself, which in turn
guarantees its mechanical response to increased fluid
filtration [34].
Glycosaminoglycans and the mechanical
properties of lung parenchyma
Lung parenchymal tissues exhibit prominent viscoelastic
behaviour. The anatomical elements potentially responsible
for this behaviour include the collagen-elastin-proteoglycan
matrix, the surface film and contractile elements in the lung
periphery [2,35].
The viscoelastic characteristics of the parenchymal tissues
may be attributed, at least in part, to GAGs [36]. For
instance, GAGs are highly hydrophilic and have the ability to
attract ions and fluid into the matrix and thus affect tissue
viscoelasticity; furthermore, the arrangement of fibres within
the connective tissue matrix associated with GAGs also
enhances viscoelasticity. It seems that the energy dissipation
occurs not at the molecular level within collagen or elastin but
rather at the level of fibre-fibre contact and by shearing of
GAGs, which provide the lubricating film between adjacent
fibres [37].
In order to study the effects of different GAGs on the
mechanical tissue properties of lung parenchyma, specific
degradative enzymes to digest GAGs have been used. Tissue
resistance and hysteresivity increased in lung tissues treated
with chondroitinase or heparitinase, whereas the quasi-static
elastance was augmented only by chondroitinase.
Conversely, exposure to hyalurodinase yielded no effect on
mechanical behaviour of the lung parenchyma. These data
suggest that the resistive properties of lung parenchyma are
influenced mainly by both chondroitin sulphate and heparan
sulphate [38], and elastance by chondroitin sulphate only.
Glycosaminoglycans and mechanical ventilation
Changes in the components of ECM play an important role in
ventilation-induced lung injury. Berg and coworkers [39] and
Parker and colleagues [40] observed that abnormal
ventilation regimens induced activation of matrix components.
Furthermore, mechanical ventilation with increased tidal
volumes led to increased levels of versican, heparan sulphate
proteoglycans and byglican [38]. These studies suggest that
abnormal ventilation induces changes in ECM components,
including GAGs, even in normal lungs. In Figure 3 we
summarize the effects of hydraulic oedema and lesional
oedema on spontaneous breathing, and on physiological and
injurious mechanical ventilation, both early and late in the
course of lung injury. During hydraulic oedema and in the
early phase of lung injury, the prevalent lesion is
fragmentation of chondroitin sulphate, whereas in lesional
oedema heparin sulphate is more damaged. Mechanical
ventilation at ‘physiological’ tidal volume (7 ml/kg) led to
fragmentation mainly of chondroitin sulphate proteoglycan.
However, the ongoing mechanical ventilation resulted in
fragmentation of both GAGs, leading to ECM disorganization.
Interestingly, although the lymphatic flow drainage is reduced,
the wet weight:dry weight ratio remained unaltered [41]. On
the contrary, with ‘injurious’ mechanical ventilation, at the
early phase of lung injury, fragmentation of both chondroitin
sulphate and heparan sulphate proteoglycans occurs, which
is partially compensated for by an increase in the synthesis of
new GAGs. During the course of lung injury greater
fragmentation of GAGs takes place, with an increase in the
wet weight:dry weight ratio and progressive fibrogenesis [42]
(Figure 3).
Biological roles of glycosaminoglycans
GAGs interact with an enormous number of proteins, ranging
from proteases, extracellular signalling molecules, lipid-
binding and membrane-binding proteins, and cell-surface
receptors on viruses. Their functions include modulating
signal transduction associated with processes such as
development, cell proliferation and angiogenesis; and
adhesion, localization and migration of cells. In addition, they
act directly as receptors and assembly factors, and they are
used by many pathogens for localization and entry into cells
[18]. Furthermore, extracellular GAGs can potentially
sequester proteins and enzymes, and present them to the
appropriate site for activation [43] (Table 1).
Interactions of specific proteins with glycosaminoglycans
GAGs interact with proteins to modulate their activity. In this
context, the interaction between FGFs and their tyrosine
kinase receptors depends on the sequence of the heparan
sulphate chain [18]. Heparan sulphate plays a critical role in
FGF signalling by facilitating the formation of FGF-FGF
receptor complexes (and/or stabilizing these complexes) and
enhancing (and/or stabilizing) FGF oligomerization [43]. In
addition, in the ECM heparan sulphate binds FGF, storing it
in an inactive form until needed, thereby allowing rapid
response to stimuli [44].
Another well studied example of protein-GAG interaction
involves the binding of antithrombin to heparin/heparan
sulphate, which results in the inactivation of the coagulation
cascade. Heparan sulphate also regulates other aspects of
the cardiovascular homeostasis by interacting with additional
proteins, including apolipoproteins and lipoprotein lipase
Available online http://ccforum.com/content/10/6/237
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[45]. Growth factors such as hepatocyte growth factor,
platelet-derived growth factor, epidermal growth factor, and
vascular endothelial growth factor [46-48] also bind heparin
and heparin sulphate, although the physiological consequences
of this binding are unclear.
Heparan sulphate interacts with cytokines such as interleukin
(IL)-5, IL-6, IL-8, IL-10, tumour necrosis factor (TNF)-α and
platelet factor-4 [49-51]. The interaction of heparan sulphate
with IL-8 promotes the activity of the cytokine, whereas, in the
case of platelet factor-4, the interaction inhibits the activity.
Heparan sulphate has been shown to interact with various
ECM proteins, including fibronectin, laminin, thrombospondin,
collagen types I, II, IV, V, VI, XIII and XVIII, and endostatin. The
binding of endostatin by heparan sulphate is important for its
antiangiogenic function [52]. The interaction between
heparan sulphate and laminin could be important in
determining the integrity of basement membranes [53]. The
interaction between heparan sulphate and collagen V plays
an important role in the modulation of cell adhesion to the
substratum [54]. Furthermore, it has been demonstrated that
chondroitin sulphate could also bind to collagen V, participa-
ting in the regulation of cell adhesion to the ECM [55].
Chemokines are a subset of cytokines that are known to
interact with GAGs. Although chemokines bind to high-
affinity G-protein-coupled receptors on migrating cells, it has
been hypothesized that they bind to immobilized GAGs as a
mechanism for cell-surface retention and possibly for presen-
tation to circulating leucocytes. Without such a mechanism,
chemokine gradients would be disrupted by diffusion,
especially in the presence of shear forces in the blood
vessels and draining lymph nodes. Chemokine immobilization
is necessary because soluble chemokines could haphazardly
bind and activate leucocytes prior to selectin-mediated
adhesion, subsequent arrest and firm adhesion, and therefore
transmigration of the leucocyte would not occur. Furthermore,
interactions with GAGs may also provide another level of
specificity and control over cell migration [56].
GAGs have also been shown to protect chemokines from
proteolysis and may serve as an additional layer of regulation.
Similarly, some chemokines are released as high-molecular-
weight complexes associated with proteoglycans, and
heparin and heparan sulphate can inhibit chemokine function;
these findings suggest that some GAG interactions can
prevent inappropriate chemokine activation. Such complexes
Critical Care    Vol 10 No 6 Souza-Fernandes et al.
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Figure 3
Changes in extracellular matrix. Illutrated are changes in the extracellular matrix that occur during hydraulic and lesional oedemas in spontaneous
breathing (SB) and physiological and injurious mechanical ventilation (MV) early and late in the course of lung injury. Bold lines represent the new
synthesis of heparan sulphate (HS)-proteoglycan (PG) or chondroitin sulphate (CS)-PG. During hydraulic oedema and in the early phase, the
prevalent lesion is fragmentation of CS, whereas in the lesional oedema HS is damaged. In physiological  MV, mainly CS-PG was fragmented, but
the ongoing MV yields the fragmentation of both glycosaminoglycans. During injurious MV, although HS-PG and CS-PG are injured, collagen fibre
content increases early and late in the course of lung injury. Thus, we hypothesize that in the early phase of lung injury collagen fibre synthesis
could be beneficial in avoiding the rupture of glycosaminoglycans, minimizing interstitial oedema formation. Pi, interstitial pressure; W/D, wet
weight:dry weight ratio.
may also serve as storage forms for rapid mobilization of
chemokines without the need for protein synthesis [18].
Heparin and inflammation
There is increasing evidence that heparin has a wide range of
biological properties that can be considered beneficial in the
context of the regulation of the inflammatory response [57].
Heparin can inhibit the influx of neutrophils into certain
tissues and inhibit T-cell trafficking, partly by an inhibitory
effect on the heparinase enzyme secreted by T cells [58].
Furthermore, heparin has been shown to be released from
human lung mast cells in response to allergen exposure, and
increased levels of a heparin-like substance have been
reported in the plasma of asthmatic individuals [59]. Heparin
can also inhibit allergen-induced eosinophil infiltration into the
airways of experimental animals [60].
After the inflammatory cells have passed through the lung
tissue, it is recognized that there is a number of stages
involved, including adhesion to the vascular endothelium,
diapedesis across the endothelial cells and chemotaxis within
tissues. It is clear that heparin can inhibit all stages of cell
migration, including the carbohydrate-selectin interactions
between endothelial cells and leucocytes, the presentation of
specific chemoattractants to activated leucocytes, and
leucocyte trafficking. Although the mechanisms that underlie
the effect of heparin on neutrophil migration are well
understood, the ability of heparin to interfere with eosinophil
adherence is less well understood. Nonetheless, heparin is
able to inhibit the actions of several important eosinophil
chemoattractants, such as platelet factor-4 [58].
Although the precise mechanism of the anti-inflammatory
effects of heparin is not established, it has been suggested
that inhibition of the interaction between proinflammatory
cytokines and membrane-associated GAGs may provide a
mechanism for inducing clinically useful immunosuppression.
Whereas immobilized heparin is essential for the biological
activity of chemokines, soluble heparin has been shown to
inhibit the biological effects of chemokines [56]. It is therefore
Available online http://ccforum.com/content/10/6/237
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Table 1
The main characteristics of glycosaminoglycans
GAG Structure Function [references]
HA D-glucuronate + GlcNAc Stabilization of the connective tissue [11]
Organization of the ECM [11]
Hydration and water homeostasis [11]
Receptor-mediated signalling [12]
Morphogenesis and tissue homeostasis [13,14]
Regulation of the inflammatory response [15]
Tissue modelling and remodelling [72]
Cellular migration and fagocytosis [5]
DS L-iduronate + GalNAc-4-sulphate Collagen organization [18]
Regulation of TGF-β activity [5]
Stabilization of the basement membrane [18]
Regulation of cell-cell and cell-matrix interactions [5]
CS D-glucuronate + GalNAc-4- or 6-sulphate Prevention of inflammation [55]
Immune modulation [43]
Maintenance of the structure and function of cartilage [55]
Cartilage shock-absorbing properties [55]
Regulation of cell adhesion to the ECM [55]
HS D-glucuronate-2-sulphate (or iduronate-2-sulphate) + Interaction with cytokines, chemokines and interleukins [18,44-52]
N-sulfo-D-glucosamine-6-sulphate Morphogenesis, development and organogenesis [19]
Coreceptors for various receptor tyrosine kinases [27]
Heparin D-glucuronate-2-sulphate (or iduronate-2-sulphate) + Anticoagulant effects [19]
N-sulfo-D-glucosamine-6-sulphate Stabilization of some mast cell tryptases [22]
Modulation of the activity of various mast cell chymases [59]
Regulation of the inflammatory response [57]
Remodelling of the airway wall in asthma [58]
KS Galactose + GlcNAc-6-sulphate Tissue hydration [115]
Cell biology [115]
Most abundant GAG in airway secretion [116]
CS, chondroitin sulphate; DS, dermatan sulphate; ECM, extracellular matrix; EGF, epidermal growth factor; FGF, fibroblast growth factor; GAG,
glycosaminoglycan; GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine; HA, hyaluronic acid; HGF, hepatocyte growth factor; HS,
heparan sulphate; KS, keratan sulphate; PDGF, platelet-derived growth factor; TGF, transforming growth factor; VEGF, vascular endothelial growth
factor.
likely that the anti-inflammatory effects of heparin are
mediated, at least in part, by interference with the chemokine
system [18].
Therapeutic aspects of heparin
The effectiveness of heparin in blocking fibrin deposition in the
lung, with subsequent improvement in lung function, has been
studied. Large doses of unfractionated heparin (500 units/kg)
have been demonstrated to block fibrin deposition effectively in
the lungs and to prevent an increase in extravascular lung water
in dogs after microembolization [61]. Other authors, using
higher doses of heparin (3000 units/kg) or fibrinogen depletion
by viper venom, could not demonstrate a reduction in
extravascular lung water in a microemboli model in sheep [62].
Heparin has also been evaluated in an ovine smoke inhalation
model [63]. Smoke inhalation induces tracheobronchial
obstruction and increases pulmonary microvascular
permeability and oedema. This is thought to be mediated by
the release of proteases, such as elastase, and free oxygen
radicals. High-dose heparin (400 units/kg bolus), followed by
continuous infusion to maintain an activated clotting time of
250 to 300 s, was associated with an improvement in partial
arterial oxygen tension/fractional inspired oxygen ratio at 12
to 72 hours compared with controls. Tracheobronchial casts
and pulmonary oedema were reduced, but leucocyte lung
infiltration and oxygen free radical activity were unaffected by
heparin [64].
In a lavage and volutrauma-induced lung injury model in
piglets, heparin (30 units/kg) was compared with anti-
thrombin alone and with antithrombin combined with heparin
[65]. Surprisingly, gas exchange was improved and hyaline
membrane formation was reduced by heparin alone
compared with antithrombin alone or antithrombin combined
with heparin. However, these data were not confirmed by two
other studies that explored the effects of intravenous or
inhaled heparin in endotoxin or smoke inhalation induced lung
injury models [66,67]. Heparin prophylaxis (5000 units every
8 hours for 7 days) before and after lobectomy for non-small-
cell lung carcinoma was associated with reduced plasma
levels of neutrophil elastase, which may protect the lung from
complications such as acute respiratory distress syndrome
(ARDS) [68].
Hyaluronic acid
Hyaluronic acid in the pulmonary alveolus
The duplex nature of the lining of the pulmonary alveolus has
long been appreciated. Surfactant is present at the interface
with air, where it prevents the alveolar collapse by lowering
surface tension. Surfactant rests on an aqueous subphase and
forms a smooth, continuous surface over the projections of the
epithelial cells. There is a constant requirement to replace
losses to the surfactant layer brought about by the cyclic
compression and expansion of breathing. Type II cells in the
wall of the alveolus are specialized to produce surfactant and
they also secrete hyaluronic acid into the subphase [18].
Hyaluronic acid is also known to attract the polar heads of
surfactant phospholipids and has hydrophobic regions, which
could bind to the hydrophobic surfactant proteins B and C.
These direct interactions of hyaluronic acid and surfactant
phospholipids contribute to the stability of the surfactant layer
[69]. Thereafter, hyaluronic acid interacts with itself and with
proteins in the subphase to form a hydrophilic gel. At the
epithelial cell layer, the components are concentrated because
of tethered hyaluronic acid molecules and the gel smoothes
over cell projections. At the air interface, the components are
so dilute that a layer of essentially water is present [7].
Hyaluronic acid in response to injury
During the maturation of tissue and organs there is a fall in
water concentration, suggesting that mature organs are
adapted to function in an environment with a considerably
lower amount of water than in early foetal life. Based on this,
and on the observation that synthesis of hyaluronic acid is a
very early response to connective tissue cell activation in vitro,
a rather attractive hypothesis is that inflammation and tissue
repair (processes that involve migration and proliferation of
cells and that require a vast array of paracrine mechanisms)
require an environment with a water concentration
considerably higher than that of many mature organs. From
this point of view, both the permeability increase in the
microvasculature and the increased synthesis of hyaluronic
acid would synergize to achieve an overhydration of the
interstitium, contributing to the inflammatory mechanism [11].
That the overall synthesis of hyaluronic acid in the organism is
considerable and that the hyaluronic acid pool of the
interstitium has a very short half-life [70,71] suggest that the
concentration of hyaluronic acid in the interstitium is in a
dynamic equilibrium, where synthesis and elimination are in
balance. Because various cytokines have been observed to
influence the synthesis of hyaluronic acid by connective
tissue cells in vitro [72], an attractive hypothesis is that the
synthesis of hyaluronic acid in vivo is altered in inflammatory
and immunological conditions where there is increased
cytokine release. Other data suggest that the run-off or
elimination of hyaluronic acid from the tissue compartments is
enhanced by a common feature in the inflammatory process,
namely increased interstitial water flux. These observations
suggest that an ongoing inflammatory state is associated with
an increased turnover of hyaluronic acid in the affected tissue
compartment. Furthermore, these data suggest that modula-
tion of the tissue concentration of hyaluronic acid might be a
mechanism by which the organism can modulate the
behaviour of the interstitium, and thereby create differences in
the environment where inflammation, tumour growth and
tissue repair take place.
To function in tissue modelling during development, as well
as in normal tissue homeostasis and remodelling in disease,
hyaluronic acid interacts with a number of hyaluronic acid-
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binding proteins called hyaldherins [73]. The hyaldherin
molecules include structural matrix hyaluronic acid-binding
proteins as well as cell surface receptors that bind with high
affinity to hyaluronic acid [74]. Many cell surface receptors for
hyaluronic acid have been detected in a variety of cells and
tissues [73]. Among these, the CD44 family has been better
characterized. Turley and coworkers characterized hyaluronic
acid receptors that mediate cell locomotion [35]. Lacy and
Underhill [74] demonstrated a chemically significant relation-
ship between a receptor for hyaluronic acid and the cyto-
skeleton of cells through actin filaments. They showed that
the receptor for hyaluronic acid is directly or indirectly
associated with cytosolic actin filaments. This association
suggests that there is a transmembrane interaction between
hyaluronic acid outside of the cell and the actin filaments
inside, which could explain the effect of hyaluronic acid on
cellular activities such as migration and phagocytosis [5].
Several studies have demonstrated that the biological effects
of hyaluronic acid appear to vary depending on the average
molecular mass [5,8,12,75-79]. In physiological conditions,
hyaluronic acid is a polymer with high average molecular
mass, in excess of 106 Da. However, following tissue injury,
hyaluronic acid fragments of lower molecular mass
accumulate. Ohkawara and coworkers [77] demonstrated
that small-molecular-weight fragments increase the survival of
peripheral blood eosinophils in vitro. They also observed that
molecules of higher molecular weight were much less
effective. Tammi and coworkers [12] showed that fragmented
hyaluronic acid with an average molecular mass of
250,000 Da can induce the expression of inflammatory genes
[12]. Low-molecular-weight fragments can stimulate activated
macrophages to express RNAs of numerous chemokines and
cytokines, including the production of metalloelastase [76].
However, fragments of higher molecular weight have an
opposite effect and suppressed such chemokine expression
[5]. Horton and coworkers [78] reported that small-
molecular-weight fragments of hyaluronic acid would serve to
modulate macrophage functions through nuclear factor-κB
signalling synergistically with interferon-γ [78].
Nevertheless, biological relevance is suggested by reports
showing that fragmented hyaluronic acid, which induces
inflammatory gene expression in vitro is in the same size
range as hyaluronic acid that accumulates under inflammatory
conditions in vivo [76]. A common theme appears to be that
low-molecular-weight hyaluronic acid can initiate gene
transcription, influencing cell proliferation and migration.
Generation of hyaluronic acid fragments under conditions of
inflammation or tumourigenesis, or tissue injury as a result of
hyaluronidases or oxidation [75] may then signal to the host
that normal homeostasis has been profoundly disturbed.
Hyaluronic acid and mechanical ventilation
Mascarenhas and coworkers [79] observed that high tidal
volume ventilation of rat lungs caused changes in their
production of hyaluronic acid, with increased levels of
fragments of lower molecular mass. They also showed that
these fragments induced IL-8 production in a dose-
dependent manner in human type II-like alveolar epithelial
cells, contributing to the pathogenesis of ventilator-induced
lung injury [79]. Furthermore, Bai and coworkers [8]
demonstrated that high tidal volume ventilation induced the
appearance of low-molecular-weight hyaluronic acid and
resulted in neutrophil infiltration in the lungs. These effects
were not observed in hyaluronic acid synthase-3 knockout
mice. They concluded that high tidal volume induced low-
molecular-weight hyaluronic acid production is dependent on
de novo synthesis through hyaluronic acid synthase-3, and
plays a role in the inflammatory response of ventilator-induced
lung injury [8]. Thus, we can observe that an inflammatory
reaction, irrespective of its cause, is followed by an increased
synthesis of hyaluronic acid in the interstitium [11].
Hyaluronic acid in respiratory diseases
Sepsis
Sepsis is the leading cause of mortality in intensive care units
and is generally considered to result from excessive activation
of the host’s inflammatory defence mechanisms. Dissemi-
nated intravascular coagulation (DIC) frequently complicates
sepsis. DIC is an acquired syndrome characterized by the
activation of intravascular coagulation, culminating in intra-
vascular fibrin formation and deposition in the micro-
vasculature. Fibrin deposition leads to a diffuse obstruction of
the microvascular bed, resulting in progressive organ
dysfunction, such as the development of renal failure and
ARDS, hypotension and circulatory failure. Because DIC is
involved in the pathogenesis of sepsis and the development
of multiple organ dysfunction syndrome, inhibition of coagula-
tion seems a valuable therapeutic option. The hallmark of the
coagulation disorder in sepsis is the imbalance between
intravascular fibrin formation and its removal. Anticoagulant
mechanisms deprive the activated coagulation system of
thrombin. Thrombin is quickly inactivated by antithrombin by
formation of thrombin-antithrombin complexes, which are
rapidly cleared from the circulation. Moreover, thrombo-
modulin expressed on endothelial cells binds thrombin and
abrogates its procoagulant activity [80]. The thrombin-
thrombomodulin complex activates protein C, and activated
protein C (APC) rapidly dissociates from the thrombomodulin-
thrombin complex and inactivates factors Va and VIIIa, thereby
decreasing thrombin generation [81]. Moreover, APC
enhances fibrinolysis by neutralization of plasminogen
activator inhibitor type 1 [80]. During sepsis, several of these
anticoagulant mechanisms are severely compromised.
Inactivation of antithrombin by elastase released from
activated neutrophils and consumption of antithrombin
caused by the rapid clearance of thrombin-antithrombin
complexes decrease the availability of functional antithrombin.
The function of the APC system is also severely
compromised during sepsis. Reduced thrombomodulin
expression on endothelial cells to inflammatory mediators,
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such as TNF-α, has been claimed to explain the decreased
APC activity [80].
Because activation of coagulation during sepsis is mainly
initiated through the extrinsic pathway, the tissue factor
pathway inhibitor (TFPI) has attracted some interest. In the
circulation, TFPI originates from at least three pools. The
majority is bound via GAGs to endothelial cells in the
microvasculature, and a small fraction circulates either
associated with lipoproteins or in platelets. Although normal
or even elevated levels of TFPI can be found in DIC and
sepsis, elevated tissue factor levels can be measured in the
plasma of these patients, suggesting a relative deficiency of
TFPI to neutralize tissue factor, which finally results in
unopposed thrombin generation [80]. Restoration of
anticoagulant capacity as well as fibrinolysis might be a
promising target for therapeutic strategies in sepsis. Thus,
administration of coagulation inhibitors might be an attractive
therapeutic approach to human sepsis. Based on these facts,
a large, double-blind, placebo-controlled multicentre trial [82]
was conoducted to investigate the effect of antithrombin,
together with heparin, in patients with sepsis. Although
considerable antithrombin levels 24 hours after administration
had been achieved, no difference in mortality rate was found.
Moreover, patients treated with antithrombin had significantly
more bleeding complications compared with the placebo
group. In the group of patients with antithrombin activity
levels above 60%, a beneficial effect on 90-day mortality was
found, which can be explained by the higher levels achieved
by antithrombin administration in these patients, as compared
with patients starting with levels below 60%. In subgroup
analysis, patients without heparin exhibited a mortality risk
reduction of approximately 15%. A probable explanation is
that the concomitant use of heparin decreases the ability of
antithrombin to bind to GAG on endothelial cells [80].
Antithrombin must bind to GAGs on endothelial surface or
inflammatory cells to exert its anti-inflammatory effects.
Heparin competitively inhibits the binding of antithrombin to
other GAGs and eliminates the anti-inflammatory effects of
antithrombin [83]. Moreover, patients treated with anti-
thrombin receiving no heparin had fewer bleeding complica-
tions as compared with patients receiving heparin [80].
Patients with severe sepsis and with a predicted high risk of
death have a treatment benefit from high-dose antithrombin III
(ATIII). In this population, an absolute risk reduction in 56-day
all-cause mortality was observed, and the treatment effect
was maintained until 90 days after randomization [84]. The
treatment effect in favour of ATIII was observed even with
concomitant use of heparin, which has been shown to
antagonize the anti-inflammatory activities of ATIII. ATIII may
directly affect inflammatory cell functions by ligation of ATIII-
binding GAGs, including members of the syndecan family of
heparin sulphate proteoglycans. Syndecans are surface
molecules in a variety of cell types, including leucocytes and
endothelial cells, which mediate cell-cell adhesion and are
involved in proliferation, migration, and differentiation.
Heparins may prevent ATIII from binding to syndecans. The
only serious adverse event significantly associated with ATIII
administration was bleeding, but bleeding did not necessarily
translate into increased mortality in the ATIII group.
Sepsis generates a procoagulant state by multiple other
mechanisms. TNF-α is principally responsible for activation of
the fibrinolytic pathways in systemic inflammatory states.
Thrombin-antithrombin complex formation is accelerated by
the heparan sulphate found on the endothelial surface.
Through its interaction with this GAG, antithrombin may
stimulate the production of prostacyclin by endothelial cells.
Prostacyclin has anti-inflammatory properties, including
diminishing TNF-α synthesis from monocytes, inflammatory
mediator release from neutrophils and neutrophil adhesion to
endothelial cells [85].
Sepsis induced by endotoxins such as lipopolysaccharide
(LPS) is characterized by enhanced production of inflam-
matory mediators, including phospholipase A2 (PLA2), TNF-α,
IL-1 and IL-6. It is known that LPS, either directly or mediated
by TNF-α or IL-1, upregulates the expression of adhesion
molecules on the endothelial surface and increases the
production of chemokines in situ, thereby promoting an inflam-
matory response in organs such as kidney and lung [86].
Among the mediators involved in the pathophysiology of
sepsis, PLA2 appears to play a key role. PLA2 hydrolyzes
membrane phospholipids to produce fatty acids, including
arachidonic acid and lyso-phospholipids, and thus it initiates
the production of numerous inflammatory mediators including
arachidonic acid derived eicosanoids (prostaglandins,
thromboxane and leukotrienes), platelet-activating factor and
the various lyso-phospholipids themselves. PLA2 additionally
synergizes with other proinflammatory mediators of tissue
damage. It has been suggested that degradation of cell
surface GAGs by reactive oxygen species and heparinase
renders the cell membrane accessible to the action of
exogenous PLA2 and executes the actual cell lysis and tissue
damage. Furthermore, PLA2 also facilitates extravasation of
inflammatory cells, which is a key process in the development
of sepsis and inflammation in general [87].
Infant respiratory distress syndrome
Although surfactant replacement has revolutionized the
therapy of respiratory distress syndrome of premature infants,
the effects of surfactant therapy are less dramatic when it is
used to treat lung diseases associated with ARDS. The less
successful clinical response in these diseases may be due, in
part, to surfactant inactivation caused by leakage of plasma
and inflammatory products into the alveoli. In this context,
because of the direct interactions of hyaluronic acid and
surfactant phospholipids, the administration of hyaluronic acid
together with surfactant is able to improve substantially the
surface activity of surfactant, contributing to its stability [69].
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Lu and coworkers [88] investigated the effects of using
hyaluronic acid mixture in vitro and in vivo with meconium as
the injury-producing substance. They observed that addition
of hyaluronic acid to surfactant improves surface activity in
the presence or absence of meconium. The degree of the
effect depends on the concentration and molecular weight of
hyaluronic acid. At the higher concentration, all molecular
weights of hyaluronic acid were effective, whereas at the
lower concentration only the hyaluronic acid with the greatest
molecular weight had beneficial results. In animal
experiments, hyaluronic acid added to surfactant improved
gas exchange measurements and lung mechanics.
Various properties of hyaluronic acid may account for the
alterations produced in surface activity of the surfactant.
Hyaluronic acid is known to bind to water at many times its
own weight. By binding to water molecules, hyaluronic acid
may increase the concentration of other large molecules in
the nonbound water, including the surfactant, and thus
induce its inactivation. Furthermore, phospholipids can
interact with hyaluronic acid to form complexes. The
formation of phospholipid-hyaluronic acid aggregates may
stabilize surfactant phospholipids at the air-water interface
and/or increase surface adsorption of subphase lipids.
Hyaluronic acid has hydrophilic properties and hydrophobic
regions generated by its molecular shape that could
potentially serve as interaction sites for the hydrophobic
surfactant proteins B and C [88].
Pneumonia
Hyaluronic acid stimulates the activity of blood neutrophils
such as phagocytosis and free oxygen radical formation and
migration. Based of these findings, Venge and coworkers
[89] tested the hypothesis that hyaluronic acid administration
subcutaneously might reduce the number of bacterial
infections in patients with an increased susceptibility to such
infections. Patients with chronic bronchitis and recurrent
acute exacerbation of their disease treated with hyaluronic
acid had significantly fewer acute exacerbations than did
placebo-treated patients. Those investigators concluded that
hyaluronic acid reduces the consumption of antibiotics and
the number of infectious exacerbations in patients with
chronic bronchitis, possibly by enhancing cellular host
defence mechanisms [5].
Cywes and coworkers [90] reported that CD44, a hyaluronic
acid binding protein that mediates human cell-cell and cell-
ECM binding interactions, functions as a receptor for group A
streptococci (GAS) colonization of the pharynx in vivo. The
recognition of CD44 as a receptor for a major microbial
pathogen adds a new dimension to the multifaceted role of
CD44 in cell-cell communication. The interaction between
the GAS capsular polysaccharide and CD44 is a striking
example of microbial adaptation to survival within the host
through subversion of a host intercellular communication
pathway. Interventions designed to disrupt that interaction
represent a novel potential approach to the prevention of
GAS infection [90].
Acute respiratory distress syndrome
During experimental induction of bleomycin-induced alveolar
injury in rats, there was considerable augmentation of high-
molecular-weight hyaluronic acid in the oedematous
interstitial alveolar space during the alveolitis phase [91],
which was attributed to alveolar interstitial fibroblast-like cells.
Experimental studies demonstrated a link between the
alveolar and interstitial accumulation of hyaluronic acid and
the intra-alveolar oedema [92]. The hypothesis that interstitial
water trapped by hyaluronic acid may result in impaired lung
function is further supported by the clinical observation of a
close relationship between large amounts of hyaluronic acid
recovered by bronchoalveolar lavage fluid and reduced gas
diffusion of the lung in patients with acute alveolitis or ARDS
[93]. Another study of a bleomycin model of lung injury in
mice [94] demonstrated a critical role for the hyaluronic acid
receptor CD44 in the inflammatory processes. Clearance of
hyaluronic acid fragments is crucial in resolving lung
inflammation and is dependent on CD44, which is expressed
on haematopoietic cells. In the absence of CD44, expression
of genes involved in inflammation persists, suggesting that
the signalling pathways, unlike hyaluronic acid-CD44,
regulate macrophage responses to hyaluronic acid fragments.
CD44 deficiency led to unremitting inflammation, increased
mortality rate, accumulation of hyaluronic acid, prolonged
inflammatory gene expression, decreased clearance of
apoptotic neutrophils and impaired the ability to generate
active transforming growth factor-β1. CD44 can also mediate
wound microvascular endothelial cell migration on fibrogen
and invasion into fibrin matrix [95]. In addition, several
observations suggest that CD44 may play a role in fibroblast
migration in wound healing [96]. Whether hyaluronic acid of
higher molecular weight influences the CD44 receptor in the
clearing phase of inflammation is not clear [5]. Data have
shown that CD44 is not sufficient to mediate hyaluronic acid
signalling [97]. Thus, another receptor system must be
required for hyaluronic acid signalling.
Jiang and coworkers [98] provided evidence of a requirement
for both hyaluronic acid and Toll-like receptors (TLRs), which
was stimulated by subnanomolar concentrations of LPS, in
regulating tissue injury and repair. They described two major
functions for hyaluronic acid-TLR interactions in these
processes. Soluble hyaluronic acid degradation products
generated during noninfectious lung injury can stimulate
macrophages to produce chemokines and cytokines, through
TLR2 and TLR4, which recruit neutrophils to the site of injury;
this suggests that circulating hyaluronic acid fragments could
contribute to unremitting inflammation. In addition, these data
also support a previously unrecognized role for native cell
surface high-molecular-mass hyaluronic acid and TLRs in
limiting the extent of lung epithelial cell injury by providing a
basal nuclear factor-κB activation and inhibiting apoptosis
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and promoting the repair of parenchymal cell injury through
TLR-dependent mechanisms. Altering the balance in favour of
forms of high molecular mass could favour recovery from
ARDS [98,99].
Pulmonary fibrosis
Lung fibrosis results from injury to the lung parenchyma,
increased proliferation of mesenchymal cells, and excessive
accumulation of connective tissue matrix in the interstitium
and intra-alveolar space of the lung. A combination of several
normal but exaggerated biological processes, including local
overproduction of growth factor and cytokines, coagulation
system activation, decreased fibrinolysis and excessive
oxidative stress, are believed to be involved in the patho-
genesis of pulmonary fibrosis. After injury, resident alveolar
cells, including endothelial/epithelial cells and alveolar
macrophages, secrete cytokines, chemokines, adhesion
molecules and tissue factor. Under normal conditions, this
reaction leads to temporary inflammation, tissue formation,
remodelling and, finally, normal tissue repair. However,
persistent injury and chronic inflammation may accelerate the
fibroproliferative response by promoting the secretion of
growth factors from resident lung cells, including alveolar
macrophages. These growth factors stimulate the
proliferation of fibroblasts and smooth muscle cells and the
secretion of extracellular matrix components such as
collagen, fibronectin and GAGs in the lung. The relative
insufficiency of metalloproteinases, increased secretion of
tissue inhibitors of metalloproteinases, and abnormal function
of the fibrinolysis system also play critical roles in fibro-
proliferative processes in the lung [100].
Asthma
In addition to a role in protecting against alveolar destruction
in experimental models of lung emphysema, hyaluronic acid
has also been found to block bronchial obstruction induced
by aerosol administration of pancreatic elastase in sheep
[101]. Because in vitro experiments have demonstrated that
hyaluronic acid can inactivate tissue kallikrein, it has been
proposed that the protective effects of hyaluronic acid
against elastase-induced bronchoconstriction are mediated
through the inactivation of tissue kallikrein [102]. These
studies suggest a possible therapeutic role for hyaluronic
acid in mitigating the bronchial responses induced by
elastases.
In this way, the first studies in humans with a single dose of
inhaled hyaluronic acid were suggestive of a protective effect
against exercise-induced bronchoconstriction [103,104]. The
exercise-induced bronchoconstriction is mediated by
hyperventilation, which leads to heat and/or water loss from
the airway. This causes changes in osmolarity and
temperature of the bronchial mucosa, which can stimulate
airway epithelial cells, infiltrative cells and airway nerves.
These pathways indirectly induce smooth muscle contraction
and thereby bronchoconstriction. Through its barrier
properties, hyaluronic acid may prevent heat and water loss
from the airways during exercise and could thereby protect
against exercise-induced bronchoconstriction.
Kunz and coworkers [104], however, showed that a single
dose of hyaluronic acid administered before exercise did not
protect against exercise-induced bronchoconstriction in
asthmatic patients. Another GAG, namely heparin, has been
shown to protect against exercise-induced broncho-
constriction. This inhibitory effect may be due to prevention of
mediator release rather than direct effects on smooth muscle
[104]. Furthermore, heparin may be capable of modulating
the extent of remodelling of the airway wall seen in asthma by
modulating the actions of a range of proteins including ECM
proteins, growth factors and certain enzymes, and by
inhibiting the proliferation of lung fibroblasts and airway
smooth muscle cells [58]. Additionally, heparin is released in
the airways physiologically as a homeostatic mechanism to
limit the extent of the cellular adhesion and diapedesis, and
the release of heparin provides a plausible homeostatic
mechanism to limit tissue damage and remodelling following
an inflammatory insult to the mucosal surface [57].
Mast cells are essential elements in allergic inflammation.
Mediators produced by mast cells are packaged within
secretory granules and, on activation, are released into the
extracellular environment within minutes. Principal granule
constituents include histamine, serine proteases,
carboxypeptidase A and GAGs (heparin and chondroitin
sulphate). Histamine in granules is found in ionic association
with acidic residues of the side chains of heparin and
chondroitin sulphate, and dissociates in extracellular fluids by
exchanging with sodium ions. Moreover, mast cells might
contribute to the downregulation of the allergic response in that
they produce and release IL-1 receptor antagonist, heparin and
other molecules with anti-inflammatory properties [105].
Hyaluronic acid is also important in regulating the remodelling
process in asthma. It has been found to be elevated in
asthma, and promotes a number of proinflammatory
responses, including B cell activation, enhancement of
antigen presentation, inflammatory mediator production in
macrophages and eosinophil survival. In lung fibroblasts, a
number of inflammatory mediators that are elevated in
asthma, specifically TNF-β, interferon-β and IL-1β, can
modulate hyaluronic acid production, both alone and in
combination [106,107].
Moreover, post-transcriptional regulation may play a role in
airway remodelling via upregulation of the receptors that
mediate responses to hyaluronic acid. Deposition of
hyaluronic acid and the expression of its receptor is a key
ECM axis in which post-transcriptional regulation may play an
important role in airway remodelling [105]. The expression
CD44 is increased in areas of epithelial repair in asthmatic
patients. In fact, CD44 may have an important function in
Critical Care    Vol 10 No 6 Souza-Fernandes et al.
Page 12 of 16
(page number not for citation purposes)
localizing chemokines and growth factors to disrupted
epithelium [108]. Airway epithelium-derived cells adhere to
ECM, particularly hyaluronic acid, through CD44 [109,110].
Pulmonary emphysema
In a series of studies, Cantor and coworkers [15,111,112]
demonstrated that hyaluronic acid mitigates the action of
elastases such as porcine pancreatic elastase, as well as
human neutrophil elastase and human macrophage metallo-
elastase. Air space enlargement induced by intratracheal
elastase is augmented by prior depletion of lung hyaluronic
acid. In the same way, hyaluronic acid aerosol administered
to hamsters with elastase-induced emphysema has been
shown to reduce significantly the severity of the disease.
These properties of hyaluronic acid could protect against
elastin injury, which may have significant therapeutic
potential in diseases such as pulmonary emphysema related
to α1 antitrypsin deficiency or due to smoking, as well as
cystic fibrosis. In a related observation, it is noteworthy that
the few biochemical studies of hyaluronic acid content in the
lung of patients with emphysema have demonstrated
significant reductions of this GAG [113]. One possible
cause of the depletion of hyaluronic acid in human
emphysema is the observation that exposure to oxidants and
hydroxyl radicals present in tobacco smoke rapidly degrades
hyaluronic acid to small-molecular-weight fragments and
reduces its viscosity [114].
The depletion of hyaluronic acid in the emphysematous
human lung could be a factor in the progression of pulmonary
elastolysis and pulmonary emphysema with time. Exogenous
replacement of depleted hyaluronic acid could be an
indication for its use in clinical emphysema, along with a
protective function against elastolysis from neutrophil and
macrophage elastases through a barrier mechanism for
elastic fibres [112]. It should be noted, however, that human
emphysema is a complex disease in which elastic fibre
degradation may be one of many factors that cause alveolar
destruction [5].
Conclusion
GAGs play a significant role in many pathophysiological
processes that occur in the ECM of the lung: they regulate
hydration and water homeostasis; they maintain structure and
function; they modulate the inflammatory response; and they
influence tissue repair and remodelling.
Given the great diversity of GAG structures and the evidence
that GAGs may have a protective effect against injury in
various respiratory diseases, an understanding of changes in
GAG expression that occur in disease may lead to
opportunities to develop innovative and selective therapies in
the future. From this perspective, the structure of the GAG
molecule deserves further investigation into its possible
therapeutic role in a variety of pulmonary diseases.
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